Messenger

MiRNA Sequencing and Assay Market Research 2024: Robust Growth with Emerging Trends in Personalized Medicine and Advancements in Sequencing Technologies - Global Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 3, 2024
Biotechnology, Genetics, Health, Cancer, Genomics, Prognosis, Cardiology, RNA, Traction, Research, NGS, Disease, Patient, Neurology, Data analysis, Gene expression, Diagnosis, Messenger, Biomarker, Molecular biology, Immunity, Risk assessment, Drug discovery, Medicine, Algorithm, Medical imaging

One of the primary drivers of the global miRNA sequencing and assay market is the rising demand for personalized medicine and precision diagnostics.

Key Points: 
  • One of the primary drivers of the global miRNA sequencing and assay market is the rising demand for personalized medicine and precision diagnostics.
  • This has led to a surge in the adoption of miRNA sequencing and assay technologies in both research and clinical settings.
  • The integration of bioinformatics tools has emerged as a significant driver in boosting the Global MiRNA Sequencing and Assay Market.
  • The rising interest in personalized medicine has emerged as a powerful catalyst in boosting the Global MiRNA Sequencing and Assay Market.

Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

Retrieved on: 
Wednesday, May 1, 2024
FDA, Protein, APC, MRNA, Risk, Moderna, News, Death, Partnership, Skin cancer, Vaccine, ASCO, Spyglass, AACR, NK, Lung cancer, Colorectal cancer, CNBC, NMIBC, Infection, DPX, Messenger, CD8, Merck, NSCLC, RSV, Autumn, Safety, Triangle, Survival, American Cancer Society, DNA, Therapy, Medicine, Melanoma, Pembrolizumab, Biology, Peanut, Cancer, A9, Interview, Immunotherapy, DSM-IV codes, HSV, Habit, Zika virus, COVID-19, Disease, Patent, Patient, Society, Acquisition, Peptide, Antigen, Immune system

VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-known bacteria could be behind the rising rates of cancer in people under 40, along with pointing towards bad habits such as highly-processed diets and heavy alcohol use being potential catalysts. While five-year cancer survival rates are on an upward trend, the biotech sector is racing to meet these challenges head on with new treatments and safeguards against cancer, including recent developments from companies such as BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Moderna, Inc. (NASDAQ: MRNA), Boundless Bio, Inc. (NASDAQ: BOLD), ImmunityBio, Inc. (NASDAQ: IBRX), and MacroGenics, Inc. (NASDAQ: MGNX).

Key Points: 
  • A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%.
  • "We now have massive opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases," said Kenneth Kovan, President and Chief Operating Officer of BioVaxys.
  • The joint Moderna/Merck efforts are also testing the vaccine with Keytruda against other tumor types, including non-small cell lung cancer.
  • This shot is designed to train the immune system to recognize and attack specific mutations in cancer cells.

Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

Retrieved on: 
Wednesday, May 1, 2024
FDA, Protein, APC, MRNA, Risk, Moderna, News, Death, Partnership, Skin cancer, Vaccine, ASCO, Spyglass, AACR, NK, Lung cancer, Colorectal cancer, CNBC, NMIBC, Infection, DPX, Messenger, CD8, Merck, NSCLC, RSV, Autumn, Safety, Triangle, Survival, American Cancer Society, DNA, Therapy, Medicine, Melanoma, Pembrolizumab, Biology, Peanut, Cancer, A9, Interview, Immunotherapy, DSM-IV codes, HSV, Habit, Zika virus, COVID-19, Disease, Patent, Patient, Society, Acquisition, Peptide, Antigen, Immune system

VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-known bacteria could be behind the rising rates of cancer in people under 40, along with pointing towards bad habits such as highly-processed diets and heavy alcohol use being potential catalysts. While five-year cancer survival rates are on an upward trend, the biotech sector is racing to meet these challenges head on with new treatments and safeguards against cancer, including recent developments from companies such as BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Moderna, Inc. (NASDAQ: MRNA), Boundless Bio, Inc. (NASDAQ: BOLD), ImmunityBio, Inc. (NASDAQ: IBRX), and MacroGenics, Inc. (NASDAQ: MGNX).

Key Points: 
  • A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%.
  • "We now have massive opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases," said Kenneth Kovan, President and Chief Operating Officer of BioVaxys.
  • The joint Moderna/Merck efforts are also testing the vaccine with Keytruda against other tumor types, including non-small cell lung cancer.
  • This shot is designed to train the immune system to recognize and attack specific mutations in cancer cells.

Streamlining the mRNA Manufacturing Supply Chain: Challenges and Solutions Provided by CDMOs, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, April 29, 2024
CDMO, Messenger, DNA, LNP, Plasmid, Therapy, Business development, RNA, Patient, Risk, Quality control, Vaccine

TORONTO, April 29, 2024 /PRNewswire-PRWeb/ -- Discover an informative webinar on the benefits of uniting with a contract development and manufacturing organization (CDMO) for nucleic acid-based therapeutics production.

Key Points: 
  • TORONTO, April 29, 2024 /PRNewswire-PRWeb/ -- Discover an informative webinar on the benefits of uniting with a contract development and manufacturing organization (CDMO) for nucleic acid-based therapeutics production.
  • Attendees of this event will gain insights into overcoming current program challenges while maximizing efficiency and product quality.
  • However, navigating the intricate landscape of their manufacturing processes poses significant challenges, often requiring coordination among multiple vendors.
  • Key topics include leveraging a CDMO's expertise, facilities and technology to optimize regulatory submissions, mitigate supply chain risks and enhance commercial manufacturing readiness.

DP Technology DevDay 2024 Showcases Large Science Models and Announces Open Science Initiative

Retrieved on: 
Monday, April 29, 2024
Cloud, TDC, Table, Ligand, ICLR, RMSD, CATL, Computational chemistry, DFT, RNA, Research, PDF, Artificial intelligence, DP, Intelligence, Information technology, Cloud computing, Drug discovery, BioNTech, DPA, Messenger, ADMET, Drug development, Behavior, Algorithm, Westlake University, Fine chemical

As an AI for Science pioneer, DP Technology is continually collaborating with partners to explore the transformative impact AI can bring to science.

Key Points: 
  • As an AI for Science pioneer, DP Technology is continually collaborating with partners to explore the transformative impact AI can bring to science.
  • Inspired by recent advancements of large language models, DP aspires to develop a similar foundational model for the atomic domain.
  • Industrial Software for Drug Discovery, Battery Development and beyond
    Advancing AI for Science, DP Technology has developed a suite of industry applications based on its large science models and advanced algorithms.
  • Sun Weijie, founder and CEO of DP Technology, stated, "The launch of large science models is our firm commitment to advancing scientific and industrial innovation.

EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Retrieved on: 
Friday, May 3, 2024
University, Part, CMO, Federal republic, Research, Cancer, Federal Patent Court (Germany), Vaccine, Business, Webcast, BioNTech, District court, Whole genome sequencing, Vaccination, Public, WHO, Hearing loss, Cardiology, Animal, EP 1, Omicron, GSK, Systems biology, Workforce, Infection, Messenger, Federal court, Therapy, Data monitoring committee, Safety, Monroe Dunaway Anderson, CVAC, Justice, RNA, Astrocytoma, Motion, Human, CureVac, Pandemic, GMP, Sąd rejonowy, SARS-CoV-2, Business development, Epitope, MD, Acuitas Therapeutics, DSMB, Ageing, Patent, Patient, Neurology, Operating cost, H5N1, MD Anderson Cancer Center, PPA, Interim, MBA, Antigen, COVID-19, Amgen

ET / 3 p.m. CET

Key Points: 
  • ET / 3 p.m. CET
    TÜBINGEN, Germany/BOSTON, USA – April 24, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the fourth quarter and full-year 2023 and provided a business update.
  • “We closed out 2023 on a sturdy footing and are poised to advance strongly through 2024 with strategic initiatives to make CureVac fit-for-purpose.
  • Thaminda Ramanayake was appointed to the CureVac Management Team as Chief Business Officer effective June 1, 2024.
  • Mr. Ramanayake joins CureVac from Affini-T Therapeutics, where he served as Chief Business Officer and was responsible for creating the company’s business development organization.

EQS-News: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Retrieved on: 
Friday, May 3, 2024
University, Berea College, Hearing loss, Cardiology, CVAC, Johnson & Johnson, Business development, Research, Business, CureVac, Neurology, Systems biology, Infection, Messenger, MBA, Therapy, Amgen, Pharmaceutical industry

Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas

Key Points: 
  • Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas
    TÜBINGEN, Germany/BOSTON, USA – April 24, 2024 — CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024.
  • “Thaminda’s extensive experience in advancing corporate strategy, business development and strengthening strategic partnerships in specific areas will be a tremendous asset to CureVac as we work to progress best-in-class mRNA vaccines and medicines across multiple therapeutic areas,” said Dr. Alexander Zehnder, Chief Executive Officer of CureVac.
  • He joins CureVac from Affini-T Therapeutics, where he served as Chief Business Officer and was responsible for creating the company’s business development organization.
  • With an educational background in both immunology and business, Mr. Ramanayake began his career as a scientist at Johnson & Johnson and later held a succession of Wall Street business development and consulting roles.

EQS-News: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

Retrieved on: 
Friday, May 3, 2024
University, Cell, Monroe Dunaway Anderson, CVAC, Malignancy, MD, RNA, Vaccine, IND, CureVac, Patient, Collaboration, MD Anderson Cancer Center, Assistant, Messenger, Antigen, Evolution, Drug discovery, Therapy, Whole genome sequencing, Investigational New Drug

Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need

Key Points: 
  • Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need
    MD Anderson responsible for leading initial Phase 1/2 studies; CureVac retains worldwide exclusive rights to late-stage development, commercialization, or partnering of cancer vaccine candidates
    TÜBINGEN, Germany/HOUSTON, Texas, USA – April 16, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
  • The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson’s expertise in cancer antigen discovery and validation, translational drug development, and clinical research.
  • The collaboration will focus on the development of differentiated cancer vaccine candidates in selected hematological and solid tumor indications with high unmet medical need.
  • “We are excited for cancer vaccines to potentially emerge as an essential therapeutic tool in the future,” Shukla said.

EQS-News: CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Retrieved on: 
Friday, May 3, 2024
Ageing, Infection, H5N1, Messenger, Human, CureVac, CVAC, Influenza, GSK, Safety, Virus, Vaccine

The H5N1 avian influenza virus is considered a potential future pandemic threat, known to sporadically cross species from its original bird host to other animal hosts and humans.

Key Points: 
  • The H5N1 avian influenza virus is considered a potential future pandemic threat, known to sporadically cross species from its original bird host to other animal hosts and humans.
  • The monovalent vaccine candidate is based on CureVac’s proprietary second-generation mRNA backbone and encodes an influenza A H5-antigen.
  • In the initial Phase 1 dose-escalation part of the study, up to five dose levels will be assessed compared to a placebo control.
  • It focuses on applying CureVac’s mRNA-technology to the development of new products for infectious disease targets.

EQS-News: Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next-Gen CRC Test

Retrieved on: 
Friday, May 3, 2024
FDA, Cancer, CDC, Colorectal cancer, CRC, Trial of the century, Polyp, Patient, Colonoscopy, FIT, Gene expression, Messenger, Biomarker, PMA, Medical imaging

“We conducted this pooled study to fine-tune the minimal biomarker set to be used to optimize sensitivity and specificity of the results in Mainz Biomed’s next generation CRC screening tool.

Key Points: 
  • “We conducted this pooled study to fine-tune the minimal biomarker set to be used to optimize sensitivity and specificity of the results in Mainz Biomed’s next generation CRC screening tool.
  • Hence these results represent a critical milestone on our path to launching our FDA PMA pivotal study ReconAAsense, which is planned to recruit up to 15,000 patients.
  • Each subject outcome was compared to the results from the next generation test incorporating the novel mRNA biomarkers and FIT.
  • The Company plans to publish results of this study at a major medical conference during the second quarter of 2024.